Drugs by condition
Drugs approved for pompe disease
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
4
Still marketed, NDA or BLA
Drug classes
3
Novel drugs
3
New molecular entities and new biologics
In development
1
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for pompe disease.
- Pombiliti (Cipaglucosidase Alfa-Atga) · Amicus Therap US NovelBreakthrough therapyOrphanSep 28, 2023
- Opfolda (Miglustat) · Amicus Therap US Breakthrough therapyOrphanSep 28, 2023
- Nexviazyme (Avalglucosidase Alfa-Ngpt) · Genzyme Corp NovelBreakthrough therapyPriority reviewOrphanAug 6, 2021
- Lumizyme (Alglucosidase Alfa) · Genzyme NovelPriority reviewOrphanMay 24, 2010
All approved drugs for pompe disease, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Hydrolytic Lysosomal Glycogen-specific Enzyme (2)
- Nexviazyme Avalglucosidase Alfa-Ngpt · Genzyme Corp · 2021
- Lumizyme Alglucosidase Alfa · Genzyme · 2010
Glucosylceramide Synthase Inhibitor (1)
- Opfolda Miglustat · Amicus Therap US · 2023
Class not listed in FDA's data (1)
- Pombiliti Cipaglucosidase Alfa-Atga · Amicus Therap US · 2023
Drugs in development for pompe disease
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- DNL952Phase 21 trial
Denali Therapeutics Inc. · Late-onset Pompe Disease
More on pompe disease: recruiting trials · published research
Related in rare and genetic disease: Transthyretin amyloidosis · Hereditary angioedema · Fabry disease · Gaucher disease · Phenylketonuria (PKU) · Achondroplasia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.